Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
36 HKD | +1.12% | +3.15% | -26.68% |
30/04 | Keymed Biosciences' Allergy Treatment NDA Accepted by NMPA | MT |
29/04 | Keymed Biosciences Allergy Drug Achieves Phase III Clinical Trial End Points | MT |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registrationEPS Revisions
Annual profits - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-26.68% | 1.26B | |
+9.15% | 105B | |
-1.08% | 104B | |
+5.79% | 22.94B | |
-11.55% | 22.34B | |
-7.01% | 19.25B | |
-37.08% | 17.08B | |
-9.91% | 16.96B | |
+7.55% | 14.16B | |
+40.04% | 12.63B |
- Stock Market
- Equities
- 2162 Stock
- News Keymed Biosciences Inc.
- Keymed Biosciences' Asthma, Atopic Dermatitis Treatment Gets Positive Results in Phase 1 Clinical Trial